LSW EVS 6th Annual Life Science Startup Pitch Showcase

Buffy Alegria is Co-Founder and Managing Partner of LOUD Ventures, a healthcare venture firm built for healthcare, by healthcare. A pre-med student turned corporate banker, she has served on healthcare boards, co-built one of the country’s largest women’s health-focused venture funds, and currently chairs a clinically integrated care network. The LOUD Ventures team has seen healthcare from every seat: as clinicians, board members, patients, founders, and investors. Those lived experiences shape how the firm invests. She also co-founded LOUD Collective, which pairs LOUD Ventures’ capital with hands-on execution, because she believes a check alone doesn’t build a company, and that when people and purpose come first, profits compound. A mom of three daughters based in Central Washington, she grew up in Oregon waterskiing, snow skiing, and fishing, and still spends her free time outdoors in the Pacific Northwest with her family

Dr. Charlotte Hubbert joined Lineage as Vice President of Corporate Development in April 2024. Dr. Hubbert has over fifteen years basic science research background and over fifteen years biotech venture investment experience across a broad range of sectors, therapeutic modalities, and stages. She has a proven ability to combine deep scientific expertise and business development acumen to identify innovative opportunities to drive both returns and impact.  
 
Before joining Lineage, she was on the leadership team for Business Development & Strategic Alliances at NanoString Technologies. Previous to NanoString, Dr. Hubbert was Partner and head of Gates Foundation Venture Capital, a $500 million initiative at the Bill and Melinda Gates Foundation Strategic Investment Fund, where she oversaw investing in innovative technologies that supported the foundation’s programs in global health and agriculture. Notably, she led investments and served on the board of directors of Synlogic (Nasdaq: SYBX), Sera Prognostics, Lodo Therapeutics, Agtech Accelerator, Vedanta, and Vir Biotechnology (Nasdaq: VIR). Prior to joining the Bill and Melinda Gates Foundation Strategic Investment Fund. Dr. Hubbert was a vice president at H.I.G. BioVentures, investing broadly in healthcare. She began her career in early-stage biotech, investing at Accelerator Corporation, where she was part of the founding team.  
 

Ben is a neuroscientist-turned-investor who uses a data-driven approach to identify, research, and recommend investment opportunities. At Elevate, Ben oversees investments across Elevate’s expanding funds and helps scale early-stage companies into thriving, sustainable businesses. He is well known throughout the ecosystem for his collaborative approach and commitment to serving as a mentor, advisor, and connector within Elevate’s portfolio community. 

Beyond his work at Elevate Capital, Ben has been a cornerstone of Oregon’s startup community for over a decade through his involvement with TiE Oregon Angels and TiE Global Angels, providing strategic guidance and capital insights to early-stage entrepreneurs. He currently serves on the Board of Directors for TiE Oregon, the Oregon Translational Research and Development Institute (OTRADI), and the Oregon State University Advantage Accelerator. 

Ben received his BS in Mathematical Biology from Harvey Mudd, his MBA from Portland State University, and a Doctorate in Philosophy in Neuroscience from the University of Florida.